CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 25 enrolled
Drug / intervention
Abataceptdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03882008
NCT03882008Phase 4Completed
CompareCT.gov

Phase IV Open-Label Study to Evaluate Biomarkers to Predict the Efficacy of Abatacept in Subjects With Rheumatoid Arthritis

University of Washington·interventional·Posted Mar 20, 2019·Updated Jul 30, 2024

In Brief

A Phase 4 clinical trial evaluating Abatacept for Rheumatoid Arthritis. Completed, enrolled 25 participants across 1 site.

Detailed Summary

The primary objective of this study is to evaluate if baseline levels of T cell associated biomarkers predict efficacy of abatacept during 24 weeks of treatment in patients with moderate to severe active Rheumatoid Arthritis (RA) who have had an inadequate response to conventional disease modifying anti-rheumatic drugs (cDMARDs)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesUnited States
CollaboratorsBristol-Myers Squibb

Timeline

Phase 4CompletedFinished
2020202120222023202420252026
First PostedMar 20, 2019
Enrollment StartMay 23, 2019
Primary CompletionJun 30, 2023
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 7.3 years ago

Interventions

Abataceptdrug

All the subjects will receive Abatacept subcutaneous injection once a week for 24 weeks